Maze Therapeutics, Inc. (MAZE) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $23.86: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 11.8:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 11.38; Below-average business quality; Below long-term trend.
Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases, with no approved products or product revenue. Lead program MZE829 (APOL1 inhibitor, Phase 2 for AMKD) delivered positive... Read more
Sell if holding. Engine safety override at $23.86: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 11.8:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 11.38; Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.1/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 57d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
About Maze Therapeutics, Inc.
About Maze Therapeutics, Inc.
Maze Therapeutics' lead program MZE829, an oral APOL1 inhibitor for APOL1-mediated kidney disease (AMKD), delivered positive Phase 2 topline data in March 2026, showing a mean 35.6% urinary albumin-to-creatinine ratio reduction at week 12 in evaluable patients. The company recorded no product revenue and a net loss of $131.1 million in fiscal year 2025, holding $360.0 million in cash and marketable securities at December 31, 2025. A second program, MZE782, completed Phase 1 for phenylketonuria (PKU) and CKD in September 2025.
Maze Therapeutics finances operations through equity offerings, convertible notes, debt, and nonrefundable licensing payments, having generated no product revenue since inception. In February 2026, the company entered a senior secured term loan with Hercules Capital for up to $200.0 million, with $40.0 million funded at closing; additional tranches are available through February 2031 at Prime Rate-referenced rates with floors of 7.95% to 9.25% depending on the tranche. MZE829 targets AMKD—a genetically driven CKD subtype affecting an estimated 250,000 addressable U.S. patients carrying two high-risk APOL1 variants—with no approved therapy currently available. MZE782 targets PKU and CKD, with two Phase 2 trials planned for 2026. A third program, MZE001 (S606001), was licensed to Shionogi & Co., Ltd. and is in Phase 2 development for Pompe disease.
Show full overview
Maze's enterprise value rests almost entirely on MZE829's pivotal development path: the completed Phase 2 trial enrolled only 15 patients, and a larger registrational trial must demonstrate safety and efficacy sufficient for FDA marketing approval. The Hercules Loan Agreement imposes a covenant requiring Maze to maintain unrestricted cash above 50% of outstanding principal unless market capitalization exceeds $450.0 million—a constraint that links clinical execution risk directly to refinancing capacity. Any material trial delay or FDA request for additional studies could deplete cash reserves and accelerate covenant pressure before the company reaches a commercial milestone.
See also: Healthcare · Biotechnology
From Maze Therapeutics, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-06-17Recent Developments — Maze Therapeutics, Inc.
Latest news
- NEWS Maze Therapeutics Q1 EPS $(0.45) Beats $(0.56) Estimate, Sales $20.000M Beat $9.286M Estimate — benzinga May 12, 2026 positive
- NEWS Maze Therapeutics Prices $150M Offering Of 5.54M Common Shares At $23.50 And 850K Pre-Funded Warrants At $23.499 — benzinga Apr 22, 2026 negative
- NEWS Truist Securities Maintains Buy on Maze Therapeutics, Lowers Price Target to $64 — benzinga Apr 14, 2026 neutral
Generated 2026-06-17T08:36:51Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineMZE82910-K Item 1A: 'highly dependent on the success of our lead programs ... MZE829, our most advanced lead program'
Material Events(8-K, last 90d)
- 2026-03-25Item 5.02LOWNeil Kumar appointed as Class I director effective March 27, 2026. Kumar is co-founder and CEO of BridgeBio Pharma, Inc. Routine board appointment; no departure involved.SEC filing →
- 2026-05-22Item 5.02LOWAmy Bachrodt, SVP Finance, resigned effective June 1, 2026. CFO Misbah Tahir designated as principal accounting officer upon her departure. No disagreement with company operations or financial reporting cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $23.86: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 11.8:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 11.38; Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $22.19. Score 5.1/10, moderate confidence.
Take-profit target: $54.41 (+128.0% upside). Prior stop was $22.19. Stop-loss: $22.19.
Concentration risk — Pipeline: MZE829; Quality below floor (3.4 < 4.0).
Maze Therapeutics, Inc. trades at a P/E of N/A (forward -7.3). TrendMatrix value score: 9.0/10. Verdict: Sell.
12 analysts cover MAZE with a consensus score of 4.3/5. Average price target: $63.
What does Maze Therapeutics, Inc. do?Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for...
Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases, with no approved products or product revenue. Lead program MZE829 (APOL1 inhibitor, Phase 2 for AMKD) delivered positive proof-of-concept data in March 2026; second program MZE782 completed Phase 1 for PKU and CKD in September 2025. The company held $360.0 million in cash at year-end 2025 and had accumulated a deficit of $489.5 million.